19/03/2026 Remix Therapeutics' REM-422 received the FDA fast track designation for adenoid cystic carcinoma Remix Therapeutics' REM-422 received the FDA fast track designation for adenoid cystic carcinoma ( Ref ) The US FDA granted the fast track designation to Remix Therapeutics' REM-422 (MYB mRNA degrader) for the treatment of patients with recurrent, metastatic or unresectable adenoid cystic carcinoma (ACC) whose tumors express MYB transcripts containing a poison exon. REM

17/09/2025 Rgenta Therapeutics' RGT-61159 received the FDA Orphan Drug Designation for ACC ( Ref ) The US FDA granted the Orphan Drug...